Should I buy or sell CorMedix stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRMD shares. View CRMD analyst ratings or view top-rated stocks .

What is CorMedix's stock price target for 2024?

4 brokerages have issued twelve-month price objectives for CorMedix's stock. Their CRMD share price targets range from $10.00 to $19.00. On average, they anticipate the company's stock price to reach $14.25 in the next year. This suggests a possible upside of 300.3% from the stock's current price. View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts .

How have CRMD shares performed in 2023?

CorMedix's stock was trading at $4.22 at the start of the year. Since then, CRMD shares have decreased by 15.6% and is now trading at $3.56. View the best growth stocks for 2023 here .

When is CorMedix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our CRMD earnings forecast .

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04.

What ETF holds CorMedix's stock ?

ETFMG Treatments Testing and Advancements ETF holds 12,811 shares of CRMD stock, representing 0.39% of its portfolio.

When did CorMedix's stock split?

CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN) , NVIDIA (NVDA) , AcelRx Pharmaceuticals (ACRX) , Gigamon (GIMO) , Conatus Pharmaceuticals (CNAT) , Nabriva Therapeutics (NBRV) , QUALCOMM (QCOM) , AVEO Pharmaceuticals (AVEO) , Boeing (BA) and Marvell Technology (MRVL) .

Who are CorMedix's major shareholders?

CorMedix's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.82%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.26%), Invesco Ltd. (0.10%), Rhumbline Advisers (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan. View institutional ownership trends .

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

CorMedix Stock Price, News & Analysis (NASDAQ:CRMD)

$3.56

-0.01 (-0.28%)

(As of 12/8/2023 ET)

Compare

Today's Range: $3.51
▼
$3.74
50-Day Range: $3.00
▼
$4.01
52-Week Range: $2.57
▼
$6.09

Volume: 933,766 shs
Average Volume: 568,008 shs
Market Capitalization: $195.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.25

CorMedix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 300.3% Upside
$14.25 Price Target
Short Interest: Bearish
12.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.80) to ($0.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

639th out of 954 stocks

Pharmaceutical Preparations Industry

235th out of 362 stocks

3.5

Analyst's Opinion

Consensus Rating
CorMedix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.25, CorMedix has a forecasted upside of 300.3% from its current price of $3.56.
Amount of Analyst Coverage
CorMedix has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.15% of the outstanding shares of CorMedix have been sold short.
Short Interest Ratio / Days to Cover
CorMedix has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in CorMedix has recently increased by 17.05%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CorMedix does not currently pay a dividend.
Dividend Growth
CorMedix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRMD.

3.1

News and Social Media Coverage

News Sentiment
CorMedix has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for CorMedix this week, compared to 1 article on an average week.
Search Interest
14 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CorMedix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of CorMedix is held by insiders.
Percentage Held by Institutions
Only 35.03% of the stock of CorMedix is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CorMedix are expected to decrease in the coming year, from ($0.80) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CorMedix is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CorMedix is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CorMedix has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CorMedix Stock (NASDAQ:CRMD)

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CRMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRMD Stock News Headlines

December 4, 2023 | finance.yahoo.com

CorMedix Inc. Announces Partnership With The Leapfrog Group

November 27, 2023 | msn.com

CorMedix (CRMD) Price Target Increased by 15.54% to 14.54

December 9, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 15, 2023 | msn.com

Why CorMedix Stock Popped Wednesday

November 15, 2023 | finance.yahoo.com

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

November 15, 2023 | marketwatch.com

CorMedix Shares Surge 17% on Better-Than-Expected Loss per Share

November 15, 2023 | msn.com

CorMedix rallies on FDA nod for anti-infective agent DefenCath

November 15, 2023 | reuters.com

U.S. FDA approves CorMedix's antimicrobial drug

December 9, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 15, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cormedix (CRMD), Immatics (IMTX) and Johnson & Johnson (JNJ)

November 15, 2023 | benzinga.com

Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket

November 15, 2023 | finance.yahoo.com

CorMedix Inc. (NASDAQ:CRMD) Q3 2023 Earnings Call Transcript

November 15, 2023 | finanznachrichten.de

CorMedix, Inc.: CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

November 14, 2023 | seekingalpha.com

ARCT, MNTS and SNBR are among after hour movers

November 14, 2023 | fool.com

CorMedix (CRMD) Q3 2023 Earnings Call Transcript

November 14, 2023 | finance.yahoo.com

Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities in Q3 2023

November 14, 2023 | msn.com

CorMedix GAAP EPS of -$0.17 beats by $0.04

November 14, 2023 | finance.yahoo.com

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

November 13, 2023 | msn.com

CorMedix Q3 2023 Earnings Preview

November 13, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Cormedix's earnings

November 8, 2023 | morningstar.com

Cormedix Inc CRMD

November 2, 2023 | finance.yahoo.com

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

October 11, 2023 | finance.yahoo.com

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

October 5, 2023 | markets.businessinsider.com

RBC Capital Sticks to Their Buy Rating for Cormedix (CRMD)

September 26, 2023 | finance.yahoo.com

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

September 8, 2023 | finance.yahoo.com

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

August 30, 2023 | finance.yahoo.com

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath

See More Headlines

Receive CRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRMD
CUSIP: N/A
CIK: 1410098
Web: www.cormedix.com
Phone: (908) 517-9500
Fax: 908-429-4307
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.25
High Stock Price Target: $19.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +300.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,700,000.00
Net Margins: N/A
Pretax Margin: -132,646.69%
Return on Equity: -65.98%
Return on Assets: -59.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.61
Quick Ratio: 11.61

Sales & Book Value

Annual Sales: $29,702.00
Price / Sales: 6,569.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.33 per share
Price / Book: 2.68

Miscellaneous

Outstanding Shares: 54,812,000
Free Float: 52,291,000
Market Cap: $195.13 million
Optionable: Optionable
Beta: 1.86

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Joseph Todisco MBA (Age 47)
CEO & Director
Comp: $927.62k
Dr. Matthew T. David M.D. (Age 45)
Executive VP & CFO
Comp: $830.64k
Dr. Phoebe Mounts Esq. (Age 72)
Ph.D., EVP, General Counsel, Head of Regulatory, Compliance & Legal and Secretary
Comp: $582.22k
Ms. Elizabeth Masson-Hurlburt B.A. (Age 44)
Executive VP and Head of Clinical & Medical Affairs
Comp: $538.91k
Donna Ucci
Senior VP & Head of Global Quality
Dr. Tushar Mukherjee
Senior VP & Head of Technical Operations
Ms. Erin Mistry (Age 41)
Executive VP & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CorMedix stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRMD shares.
View CRMD analyst ratings or view top-rated stocks.
What is CorMedix's stock price target for 2024?: 4 brokerages have issued twelve-month price objectives for CorMedix's stock. Their CRMD share price targets range from $10.00 to $19.00. On average, they anticipate the company's stock price to reach $14.25 in the next year. This suggests a possible upside of 300.3% from the stock's current price.
View analysts price targets for CRMD or view top-rated stocks among Wall Street analysts.
How have CRMD shares performed in 2023?: CorMedix's stock was trading at $4.22 at the start of the year. Since then, CRMD shares have decreased by 15.6% and is now trading at $3.56.
View the best growth stocks for 2023 here.
When is CorMedix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CRMD earnings forecast.
How were CorMedix's earnings last quarter?: CorMedix Inc. (NASDAQ:CRMD) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04.
What ETF holds CorMedix's stock ?: ETFMG Treatments Testing and Advancements ETF holds 12,811 shares of CRMD stock, representing 0.39% of its portfolio.

When did CorMedix's stock split?: CorMedix's stock reverse split on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of CorMedix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Amarin (AMRN), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gigamon (GIMO), Conatus Pharmaceuticals (CNAT), Nabriva Therapeutics (NBRV), QUALCOMM (QCOM), AVEO Pharmaceuticals (AVEO), Boeing (BA) and Marvell Technology (MRVL).
Who are CorMedix's major shareholders?: CorMedix's stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.82%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.26%), Invesco Ltd. (0.10%), Rhumbline Advisers (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Elizabeth Masson-Hurlburt, Joseph Todisco, Matthew T David and Myron Kaplan.
View institutional ownership trends.
How do I buy shares of CorMedix?: Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRMD) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial